Company Overview and News

24
Market Live: Nifty holds 10,550; FMCG index up 2%, Bharti Group stocks gain

2018-04-18 moneycontrol
12:55 pm Earnings Outlook: "We are looking at Sensex earnings. In Q4, earnings will grow in the range of 13-14 percent, which will be double digit growth after a long time. Partially, this will be due to low base of Q4 last year and the other due to better earnings of global commodity companies, be it energy or metals. That will aid overall growth,” Gaurav Dua, Head of Research, Sharekhan told Moneycontrol.
BAJAJ-AUTO ESL AMKD DABUR FEDA ICLQY SIMMOND DBRQY 500096 MAHSCOOTER 534816 UCLQY FEDS 500850 GODREJCP FEDERALBNK EICHERMOT GLENMARK JAGRAN 532705 FDBAY YYBKY 532822 MRZUY ULTRACEMCO 532424 532500 BAJAJFINSV TATASTEEL FORTIS TATLY MARUTI 500266 504741 BHRYY 500469 AMTEKAUTO 532978 532538 532977 BHRQY GLKQY GDRJY 505200 500470 INFRATEL BHARTIARTL INDHOTEL YESBANK ECQRY 500314 ORIENTHOT 533264 UCLQF 532648 532843 532454 TTST INDIANHUME 532296 IDEA 520077 507998

20
Market Live: Sensex consolidates after 9-day gains; hotels stocks extend rally

2018-04-18 moneycontrol
10:55 am Should gold be a part of your portfolio?: Akash Jain, Vice President - Equity Research, Ajcon Global said gold is better as a short to medium-term investment, as long-term returns on the yellow metal are often as low as 10 percent per annum. We would suggest investors not to make too heavy or long-term investments in gold.
BAJAJ-AUTO ESL DABUR 532538 532978 532977 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY 500850 BHARTIARTL INDHOTEL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 500314 ORIENTHOT 532705 533264 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

17
Market Live: Sensex off opening high, midcaps outperform; Mindtree hits new high

2018-04-18 moneycontrol
9:55 am Buzzing: Simmonds Marshall share price rallied 10 percent after ICICI Research said the company has a capital efficient business model where it realises around 3x asset turnover, realises around 12-13 percent EBITDA margins and has a working capital cycle of around 130 days.
DABUR 532538 532978 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY BHARTIARTL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 532705 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to NSE:SIMMOND / SIMMONDS MARSHALL LTD. on message board site Silicon Investor.

SMM on TSE - Simmonds Capital SMM on TSE - Simmonds Capital SMM on TSE - Simmonds Capital Simmonds Technoligies SMM/TSE Simmonds Technoligies SMM/TSE Simmonds Technoligies SMM/TSE